Population-specific factors associated with fractional excretion of uric acid.
Adult
Aged
Female
Gout
/ ethnology
Humans
Hyperuricemia
/ ethnology
Male
Middle Aged
Native Hawaiian or Other Pacific Islander
/ ethnology
New Zealand
/ ethnology
Polymorphism, Single Nucleotide
/ genetics
Polynesia
/ ethnology
Population Surveillance
/ methods
Uric Acid
/ urine
White People
/ ethnology
FEUA
Genetics
Gout
Urate
Uric acid
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
12 11 2019
12 11 2019
Historique:
received:
13
06
2019
accepted:
25
09
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
28
8
2020
Statut:
epublish
Résumé
Reduced renal clearance of uric acid is a major contributor to hyperuricemia. The aim of this study was to examine clinical and genetic variables associated with fractional excretion of uric acid (FEUA). Participants (with and without gout) in the Genetics of Gout in Aotearoa study with available genotyping and FEUA data were included (n = 1713). Ten FEUA-associated loci detected within a genome-wide association study for serum urate in a European population were analysed. A polygenic score for FEUA was calculated in each ancestry group to model the cumulative effects of the genetic variants on FEUA. Associations between FEUA and both clinical variables and polygenic score were tested using linear regression models. The mean (SD) FEUA was 5.13 (2.70) % in Eastern Polynesian participants, 4.70 (5.89) % in Western Polynesian participants, and 5.89 (2.73) % in New Zealand European participants. Although association with FEUA was observed for SLC2A9 rs11942223 in New Zealand European participants (P = 2.39 × 10 Both clinical and genetic variables contribute to renal clearance of uric acid. SLC2A9 exerts effects on FEUA variance in people of European ancestry, but not in those of Polynesian ancestry. There is a large unexplained variance in FEUA, particularly in people of Polynesian ancestry.
Sections du résumé
BACKGROUND
Reduced renal clearance of uric acid is a major contributor to hyperuricemia. The aim of this study was to examine clinical and genetic variables associated with fractional excretion of uric acid (FEUA).
METHODS
Participants (with and without gout) in the Genetics of Gout in Aotearoa study with available genotyping and FEUA data were included (n = 1713). Ten FEUA-associated loci detected within a genome-wide association study for serum urate in a European population were analysed. A polygenic score for FEUA was calculated in each ancestry group to model the cumulative effects of the genetic variants on FEUA. Associations between FEUA and both clinical variables and polygenic score were tested using linear regression models.
RESULTS
The mean (SD) FEUA was 5.13 (2.70) % in Eastern Polynesian participants, 4.70 (5.89) % in Western Polynesian participants, and 5.89 (2.73) % in New Zealand European participants. Although association with FEUA was observed for SLC2A9 rs11942223 in New Zealand European participants (P = 2.39 × 10
CONCLUSIONS
Both clinical and genetic variables contribute to renal clearance of uric acid. SLC2A9 exerts effects on FEUA variance in people of European ancestry, but not in those of Polynesian ancestry. There is a large unexplained variance in FEUA, particularly in people of Polynesian ancestry.
Identifiants
pubmed: 31718705
doi: 10.1186/s13075-019-2016-6
pii: 10.1186/s13075-019-2016-6
pmc: PMC6852918
doi:
Substances chimiques
Uric Acid
268B43MJ25
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
234Subventions
Organisme : Health Research Council of New Zealand
ID : 14-527
Pays : International
Références
Ann Rheum Dis. 1992 Mar;51(3):375-7
pubmed: 1575585
Ann Rheum Dis. 2013 Nov;72(11):1868-73
pubmed: 23349133
Arthritis Res Ther. 2015 Sep 22;17:263
pubmed: 26391224
BMJ. 2012 Jan 12;344:d8190
pubmed: 22240117
Aust N Z J Med. 1973 Aug;3(4):410-2
pubmed: 4519128
PLoS Med. 2008 Oct 7;5(10):e197
pubmed: 18842065
Arthritis Rheumatol. 2017 Jul;69(7):1461-1469
pubmed: 28371506
Arthritis Rheum. 1977 Apr;20(3):895-900
pubmed: 856219
Nat Commun. 2018 Oct 12;9(1):4228
pubmed: 30315176
J Clin Endocrinol Metab. 2008 Jun;93(6):2230-3
pubmed: 18349066
Kidney Int. 1989 Sep;36(3):378-84
pubmed: 2687564
Arthritis Res Ther. 2012 Aug 17;14(4):R189
pubmed: 22901830
Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1302-11
pubmed: 22132991
Ann Rheum Dis. 2006 Oct;65(10):1368-72
pubmed: 16644784
Diabetes. 2008 Aug;57(8):2253-7
pubmed: 18556336
Br J Pharmacol. 2008 Dec;155(7):1066-75
pubmed: 18724382
Br J Rheumatol. 1994 Oct;33(10):932-7
pubmed: 7921753
Br Med J. 1973 Feb 24;1(5851):449-51
pubmed: 4689833
Br J Rheumatol. 1984 Nov;23(4):276-82
pubmed: 6487933
BMC Musculoskelet Disord. 2017 Mar 14;18(1):108
pubmed: 28292303
Am J Kidney Dis. 2007 Aug;50(2):239-47
pubmed: 17660025
Nat Genet. 2010 May;42(5):376-84
pubmed: 20383146
J Urol. 2006 Jun;175(6):2125-8
pubmed: 16697817
PLoS Genet. 2009 Jun;5(6):e1000504
pubmed: 19503597
Ann Rheum Dis. 2016 Jul;75(7):1363-6
pubmed: 26835700
Arch Intern Med. 1998 Apr 13;158(7):741-51
pubmed: 9554680
Arthritis Rheum. 2011 Oct;63(10):3136-41
pubmed: 21800283
Hum Mol Genet. 2010 Jan 15;19(2):387-95
pubmed: 19861489
Int J Obes. 1986;10(4):255-64
pubmed: 3771090
J Am Soc Nephrol. 2007 Feb;18(2):430-9
pubmed: 17229912
Ann Rheum Dis. 2016 Jan;75(1):124-30
pubmed: 25187157
Scand J Clin Lab Invest. 2009;69(5):562-9
pubmed: 19343610
Ann Rheum Dis. 2006 Aug;65(8):981-2
pubmed: 16837492
Circ Cardiovasc Genet. 2010 Dec;3(6):523-30
pubmed: 20884846
Arthritis Rheum. 2009 Nov;60(11):3485-92
pubmed: 19877038
Nat Commun. 2016 Jan 21;7:10023
pubmed: 26831199
N Z Med J. 2018 Nov 9;131(1485):8-12
pubmed: 30408813
Lancet. 2008 Dec 6;372(9654):1953-61
pubmed: 18834626
RMD Open. 2017 Apr 11;3(1):e000424
pubmed: 28951782
Nat Genet. 2013 Feb;45(2):145-54
pubmed: 23263486
Joint Bone Spine. 2017 Mar;84(2):183-188
pubmed: 27324603